MedTrace Logo

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

NCT02060188 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 385

Last updated 2025-11-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has spread, and who have a specific biomarker in their tumors.

Conditions

  • Microsatellite Unstable Colorectal Cancer
  • Microsatellite Stable Colorectal Cancer
  • Mismatch Repair Proficient Colorectal Cancer
  • Mismatch Repair Deficient Colorectal Cancer

Interventions

DRUG

Daratumumab

Specified dose on specified days

DRUG

BMS-986016

Specified dose on specified days

DRUG

Ipilimumab

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

DRUG

Cobimetinib

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-12
Primary Completion
2024-10-22
Completion
2024-10-22
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • France
  • Ireland
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02060188 on ClinicalTrials.gov